Loading stock data…
ELUT
$1.01-0.01 (-0.98%)
Market ClosedLast close May 1
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Elutia Inc. in the Healthcare sector is trading at $1.01. The stock is currently 62% below its 52-week high of $2.64, remaining 11.4% below its 200-day moving average. Technical signals show neutral RSI of 38 and bearish MACD signal, explaining why ELUT maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 38) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.01
Potential Upside
5%
Whystock Fair Value$1.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$46.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.71
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
192.90%
Volume
Today's trading volume
50,174
Recent News
Elutia Inc (ELUT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic Moves Amid ...
Elutia Inc (ELUT) reports a 16% revenue increase and improved gross margins, while navigating operational losses and strategic product shifts.
Elutia Inc. Q4 2025 Earnings Call Summary
Moby summary of Elutia Inc.'s Q4 2025 earnings call
Elutia (ELUT) Q4 2025 Earnings Call Transcript
Earlier today, Elutia Inc. released financial results for the fourth quarter and full year ended 12/31/2025. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements contained in this call that do not relate to matters of historical fact or relate to expectations, predictions of future events, results, or performance are forward-looking statements.
Insider Spends US$74k Buying More Shares In Elutia
Whilst it may not be a huge deal, we thought it was good to see that the Elutia Inc. ( NASDAQ:ELUT ) Independent...
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know
ELUTIA INC (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).